Variable | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Age | 1.311e + 09 (0-inf) | 0.9968 |  |  |
Gender | 1.896 (0.686–5.241) | 0.2174 |  |  |
T staging | 2.629 (1.417–4.876) | 0.00217* |  |  |
N staging | 1.463 (0.4777–4.483) | 0.5051 |  |  |
M staging | 5.443 (1.161–25.52) | 0.03159* |  |  |
TNM staging | 2.434 (1.542–3.842) | 0.0001331* | 3.621 (1.388–9.447) | 0.00853* |
Maximal tumor diameter | 1.403 (1.072–1.836) | 0.0137* |  |  |
Lymph node number | 1.003 (0.9068–1.11) | 0.9527 |  |  |
Primary neoplasm focus type | 0.2495 (0.05635–1.105) | 0.06745 |  |  |
Iodine radiotherapy | 4.005e + 08 (0-inf) | 0.9991 |  |  |
Lymph node preoperative scan indicator | 1.496 (0.4241–5.273) | 0.5313 |  |  |
History of neoadjuvant treatment | 18.24 (3.976–83.66) | 0.0001871* |  |  |
CREB3L1 expression | 4.831 (1.754–13.3) | 0.00231* | 4.979 (1.074–23.08) | 0.04025* |